XML 88 R61.htm IDEA: XBRL DOCUMENT v3.25.1
SUBSEQUENT EVENTS (Details Narrative) - USD ($)
12 Months Ended
Mar. 13, 2025
Mar. 12, 2025
Feb. 14, 2025
Jan. 07, 2025
Mar. 31, 2024
Feb. 16, 2023
Dec. 31, 2024
Dec. 31, 2023
Jul. 01, 2025
Mar. 26, 2025
Mar. 04, 2025
Feb. 28, 2025
Feb. 26, 2025
Feb. 13, 2025
Jan. 31, 2025
Aug. 30, 2023
Reverse stock split outstanding shares 792,394 8,716,327     47 15,726                    
Common stock shares remained unchanged 40,000,000           40,000,000 40,000,000                
Subsequent Event [Member]                                
Reverse stock split outstanding shares 792,394 8,716,327                            
Common stock shares remained unchanged 40,000,000                              
Subsequent Event [Member] | ENvue Medical Holdings Corp [Member]                                
Debt principal amount                   $ 1,300,000            
Investments                   $ 300,000 $ 250,000   $ 250,000      
Conversion price                   $ 4.8906            
Debt interest rate                   8.00%            
Subsequent Event [Member] | Minimum [Member]                                
Conversion price                   $ 0.97812            
Common Stock [Member]                                
Number of new share issued             67,091 16,364                
Warrant exercise, conversion shares                               264,271
Exercise price per share                               $ 0.0001
Reverse stock split outstanding shares             4 1,430                
A-1 Warrants [Member]                                
Warrant exercise, conversion shares                               264,271
Exercise price per share                               $ 16.17
Securities Exchange Agreement [Member] | Subsequent Event [Member]                                
Debt principal amount                           $ 500,000    
Securities Exchange Agreement [Member] | Common Stock [Member] | Subsequent Event [Member]                                
Number of new share issued       456,478                        
Securities Exchange Agreement [Member] | Warrant [Member] | Subsequent Event [Member]                                
Warrant exercise, conversion shares                 158,562     177,773     177,773  
Securities Exchange Agreement [Member] | Pre-Funded Warrants [Member] | Subsequent Event [Member]                                
Warrant exercise, conversion shares       178,132               178,132     178,132  
Exercise price per share       $ 6.82968                        
Securities Exchange Agreement [Member] | A-1 Warrants [Member] | Subsequent Event [Member]                                
Warrant exercise, conversion shares       264,271                        
Warrant exercise price       $ 16.17                        
Merger Agreement [Member] | Subsequent Event [Member] | Series X Preferred Stock [Member]                                
Convertible shares     57,720                          
Merger Agreement [Member] | Common Stock [Member] | Subsequent Event [Member]                                
Number of new share issued     1,734,995                          
Percentage for exchange capital for consideration     100.00%                          
Merger Agreement [Member] | Common Stock [Member] | Subsequent Event [Member] | Series X Preferred Stock [Member]                                
Convertible shares     1,000                          
Convertible description     the holders of the outstanding equity of ENvue immediately prior to the First Effective Time own 19.9% of the common stock of the Company and 85.0% of the outstanding equity of the Company (assuming the Series X Preferred Stock is converting at a ratio of 1,000:1) immediately following the First Effective Time, which following Merger Stockholder Approval will allow the Series X Preferred Stock to convert to common stock of the Company which may result in the holders of ENvue to own 85% of the common stock of the Company, and (ii) the holders of the Company’s outstanding equity immediately prior to the First Effective Time own 80.1% of the common stock of the Company and 15.0% of the outstanding equity of the Company (assuming the Series X Preferred Stock is converting at a ratio of 1,000:1) immediately following the First Effective Time, which following Merger Stockholder Approval which will allow the Series X Preferred Stock to convert to common stock of the Company which may result in our holders owning 15% of common stock of the Company.                          
Merger Agreement [Member] | Common Stock [Member] | Subsequent Event [Member] | Maximum [Member]                                
Percentage for number of outstanding common stock     19.90%